CDC Advisor Reviews J&J’s Covid-19 Vaccine Risk of Blood Clots


US vaccine advisers are meeting to consider whether recommendations for use should be changed

Johnson & Johnson‘S

JNJ 0.99%

Covid-19 vaccine because of the risk a rare but serious blood clotting condition.

The Advisory Committee on Immunization Practices is hearing updates from Centers for Disease Control and Prevention officials regarding reports of J&J vaccine recipients experiencing blood clots associated with high blood pressure. low blood platelets.

The committee is expected to vote Thursday afternoon on whether to update its recommendation for the use of the J&J vaccine, according to an agenda posted online by the CDC.

Earlier this year, federal health authorities halted the use of J&J’s vaccine while they investigated the rare condition, called thrombocytopenia with thrombocytopenia syndrome, or TTS. The use of the vaccine was resumed in April after the health authority concluded Its benefits still outweigh the risks.

ACIP, which advises the CDC on vaccine policy, voted in April to continue using J&J’s vaccines, after meeting twice to discuss the issue. Risk warnings have been added to fact sheets provided to vaccine providers and recipients, including that the risk appears to be highest in women aged 30 to 49 years.

At that time, a total of 15 cases of TTS had been reported out of nearly 7 million doses of the vaccine administered. All cases occurred in women between the ages of 18 and 59, with a median age of 37 years. Symptoms develop six to 15 days after vaccination.

Partly because of safety concerns, J&J’s single-dose vaccine has been used much less frequently than the two-dose vaccine from

Moderna Inc.

mRNA -0.81%


Pfizer Inc.

PFE 2.98%

with its partner

BioNTech SE.

Recent studies have shown that the effectiveness of the Covid-19 vaccine is declining, although experts say the shots are still working well. The WSJ explains what the numbers mean and why they don’t tell the whole story. Artwork: Jacob Reynolds / WSJ

According to the CDC, about 16.1 million people in the US have been vaccinated with J&J. About 870,000 doses of J&J’s booster vaccine have been given.

J&J said in a statement Thursday it recently updated its vaccine fact sheet to say it should not be used by people who have previously experienced TTS after receiving a dose of the vaccine. earlier J&J or other vaccines of similar adenovirus-based design.

Other photos with similar designs include


PLC’s Covid-19 vaccine, available outside the US but not in the US

Write letter for Peter Loftus at

Copyright © 2021 Dow Jones & Company, Inc. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8 CDC Advisor Reviews J&J’s Covid-19 Vaccine Risk of Blood Clots

Ian Walker is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials, please contact us by email – The content will be deleted within 24 hours.

Related Articles

Back to top button